| Class / Patent application number | Description | Number of patent applications / Date published |
|---|
| 514565000 | N-N or N=C(-N)-N containing (e.g., hydrazines, hydrazones, or guanidines, etc.) | 72 |
| 20080234380 | Compositions and method for treatment of chronic inflammatory diseases - This invention defines novel compositions that can be used for clinical treatment of a class of chronic inflammatory diseases. Increased generation of carbonyl substances, namely aldehydes and ketones, occurs at sites of chronic inflammation and is common to the etiologies of all of the clinical disorders addressed herein. Such carbonyl substances are cytotoxic and additionally serve to perpetuate and disseminate the inflammatory process. This invention defines use of compositions, the orally administered required primary agents of which are primary amine derivatives of benzoic acid capable of covalently reacting with the carbonyl substances. p-Aminobenzoic acid (or PABA) is an example of the required primary agent of the present invention. PABA has a small molecular weight, is water-soluble, has a primary amine group which reacts with carbonyl-containing substances and is tolerated by the body in relatively high dosages for extended periods. The method of the present invention includes administration of a composition comprising: (1) an orally consumed therapeutically effective amount of at least one required primary agent; (2) at least one required previously known medicament co-agent recognized as effective to treat a chronic inflammatory disease addressed herein administered to the mammalian subject via the oral route; and (3) one or more additional orally consumed required co-agent selected from the group consisting of antioxidants, vitamins, metabolites at risk of depletion, sulfhydryl co-agents, co-agents which may facilitate glutathione activity and nonabsorbable primary amine polymeric co-agents; so as to-produce an additive or synergistic physiological effect of an anti-inflammatory nature. | 09-25-2008 |
| 20080300309 | Creatine Hydroxycitric Acids Salts and Methods for their Production and use in Individuals - Methods of production for Tricreatine Hydroxycitrate are disclosed. Tricreatine hydroxycitrate can be used as supplemental dietary ingredient for the purposes of reducing adiposity, suppression of appetite, improvement of muscle and exercise performance and recovery. The salts are useful in the dietetic, food supplement and food industries. | 12-04-2008 |
| 20080306159 | ENTERIC COATED, SOLUBLE CREATINE AND POLYETHYLENE GLYCOL COMPOSITION FOR ENHANCED SKELETAL UPTAKE OF ORAL CREATINE - An oral creatine formulation includes soluble creatine and polyethylene glycol, coated with an enteric coating. The most preferred soluble creatine is creatine HCl. The most preferred polyethylene glycols have an average molecular weight of from 3150 to 3685, although for particular formulation formulations and particular uses, the average molecular weight polyethylene glycols may range from 190 to 9000. | 12-11-2008 |
| 20090005450 | Use of creatine compounds for the treatment of eye disorders - The present invention provides methods of treating an eye disorder (i.e., glaucoma, macular degeneration, diabetic retinopathy, macular edema, ocular rosacea, amblyopia, cataracts, dry eye, iritis, retinitis pigmentosa, uveitis etc.) by administering a creatine compound to a subject. | 01-01-2009 |
| 20090143470 | Invisible Antimicrobial Glove and Hand Antiseptic - An alcohol based hand surgical scrub, which includes cationic anti-microbial agent preservatives, cationic polymer film-forming agents and a skin emollient, and provides a long term residual, anti-microbial “invisible glove” on the skin. The composition provides an immediate reduction in bacterial microbes. The polymer system creates an invisible film on the skin following solvent evaporation. This invisible film provides a lasting anti-microbial barrier on the skin which acts to prevent microbial growth. | 06-04-2009 |
| 20090163592 | Chiral diacylhydrazine ligands for modulating the expression of exogenous genes via an ecdysone receptor complex - The present invention provides diacylhydrazine ligands and chiral diacylhydrazine ligands for use with ecdysone receptor-based inducible gene expression systems. Thus, the present invention is useful for applications such as gene therapy, large scale production of proteins and antibodies, cell-based screening assays, functional genomics, proteomics, metabolomics, and regulation of traits in transgenic organisms, where control of gene expression levels is desirable. An advantage of the present invention is that it provides a means to regulate gene expression and to tailor expression levels to suit the user's requirements. | 06-25-2009 |
| 20090221706 | Methods of treating cognitive dysfunction by modulating brain energy metabolism - Methods for treating cognitive dysfunction by modulating brain energy metabolism are discussed. | 09-03-2009 |
| 20090253797 | CREATINE ORAL SUPPLEMENTATION USING CREATINE HYDROCHLORIDE SALT - Creatine oral supplementation using creatine hydrochloride salt, that may be added to a liquid or other beverage, or may be also used as an additive to solid oral dosages, or as a supplement, and which may be consumed by the athlete, or other party looking for immediate supplementation of strength, and may be added as a supplement within feed to livestock, in the veterinary area. | 10-08-2009 |
| 20090298943 | Use of creatine analogues and creatine kinase modulators for the prevention and treatment of obesity and its related disorders - The present invention relates to the use of creatine compounds for treating or preventing a metabolic disorder related to body weight control such as obesity, and it's associated diseases in a patient experiencing said disorder. The creatine compounds which can be used in the present method include (1) analogues of creatine which can act as substrates or substrate analogues for the enzyme creatine kinase; (2) compounds which can act as inhibitors of creatine kinase; (3) compounds which can modulate the creatine transporter (4) N-phosphocreatine analogues bearing transferable or non-transferable moieties which mimic the N-phosphoryl group. (5) compounds which modify the association of creatine kinase with other cellular components. | 12-03-2009 |
| 20090312423 | THERAPEUTIC TREATMENT FOR LUNG CONDITIONS - Methods and compositions for treating lung conditions such as bronchopulmonary dysplasia or hypoxia-induced pulmonary hypertension in a subject, including administering to the subject an effective amount of a nitric oxide precursor such as citrulline. | 12-17-2009 |
| 20090318557 | Dermatological compositions - A dermatological composition comprising a salt of a cation and an anion. The cation is derived from a monomeric or polymeric molecule that will generate an amidine moieity, a guanidine moieity or a biguanide moieity. The anion is derived from a monomeric or polymeric molecule that will generate a carboxylic acid moieity. The composition may be prepared by a metathesis or acid-base reaction. | 12-24-2009 |
| 20100022651 | Method For Increasing Hair Growth - The present invention provides a method for stimulating hair growth, which comprises applying a composition containing a combination of a creatine compound and carnitine. The composition may further comprise 5′-AMP and NADH. Such a composition is effective in stimulating cell proliferation in the hair bulb of hair plugs. | 01-28-2010 |
| 20100029768 | Compositions and Methods For Promoting Fat Loss - This invention provides diets useful for promoting fat loss in animals having a total lysine to metabolizable energy ratio of from about 6 to about 10 g/Mcal. This invention also provides compositions for promoting fat loss in animals, methods for preparing the compositions, methods for using the diets and compositions, articles of manufacture comprising the diets and compositions, and means for communicating information or instructions about such diets, compositions, methods, and articles of manufacture. | 02-04-2010 |
| 20100048709 | Treatment of Prostate Cancer with DDC Inhibitor - Prostate cancer comes in various forms and has proven difficult to treat. Provided herein are various methods and compositions for treating all forms of prostate cancers with dopa decarboxylase (DDC) inhibitors. These dopa decarboxylase inhibitors include carbidopa (α-Methyl-dopahydrazine), MFMD (α-monofluoromethyldopa), NSD-1015 (3-hydroxybenzylhydrazine), Methyldopa (L-α-Methyl-3,4-dihydroxyphenylalanine) or benserazide, and the inhibitors may be used in combination. DDC inhibitors may also be used to inhibit the progression of prostate cancer to androgen-independence and neuroendocrine prostate cancer. | 02-25-2010 |
| 20100056633 | SOLID OR AQUEOUS ALKALINE PREPARATION COMPRISING A CREATINE COMPONENT, PROCESS FOR THE PRODUCTION THEREOF AND THE USE THEREOF - A solid or aqueous alkaline preparation comprising a creatine component which comprises a buffer system which adjusts a pH of from 8.0 to 12.0 is described. The creatine is better protected with the aid of the buffer system from conversion into creatinine in the stomach. It has additionally emerged, surprisingly, that the novel formulations display a distinctly higher bioavailability and are thus taken up better by cells. Finally, the preparation of the invention has very good organoleptic properties, which in fact likewise could not be predicted. Owing to these particular advantages, the preparation of the invention is outstandingly suitable as dietary supplements, restoratives, medicinal products and feedstuffs. | 03-04-2010 |
| 20100210728 | COMPOSITION FOR TREATING A DERMAL ANOMALY - An improved composition for treatment of ulcer-type skin conditions. The composition is primarily characterized by a combination of nitroglycerin and arginine. Other embodiments comprise emollient cream, mineral oil, tumeric powder, folic acid, vitamin B12, and zinc citrate. The composition is particularly effective in improving blood flow in the underlying capillary bed about the wound, improving nerve growth about the wound, increasing circulation, and having a standardized and more predictable therapeutic characteristic. | 08-19-2010 |
| 20100227926 | Disinfectant Delivery System, and Method of Providing Alcohol-Free Disinfection - A disinfectant delivery system and method of providing alcohol-free disinfection to a body to be disinfected, as well as a method of infection reduction by preparation of a patient before an invasive procedure. A blended cloth comprising first fibers and second fibers is provided with the first fibers generally being greater in quantity by weight than the second fibers. A disinfectant solution impregnates the blended cloth, with the disinfectant solution having chlorhexidine gluconate as an active ingredient and having no alcohol. In the method according to the invention, at least one impregnated blended cloth is used to disinfect at least a portion of a body. A plurality of blended cloths can be provided for disinfecting discrete portions of the body. When an invasive procedure is to be performed on a patient, a further method according to the invention of infection reduction comprises using a CHG-impregnated cloth to disinfect at least a portion of the patient at least one day prior to the invasive procedure proximate the location of the invasive procedure. | 09-09-2010 |
| 20100261794 | COMPOSITION FOR TOPICAL USE TO ACHIEVE A RAPID AND INTENSE LIFTING EFFECT - This invention concerns a cosmetic composition for topical use containing as an active principle a blend of arginine and taurine designed to carry out an immediate “lifting” effect and able to improve in a short time the aesthetic characteristics of the cutis. The composition contains a quantity in weight of arginine of 0.05% p/p at 90% p/p, preferably from 0.5% p/p to 5% p/p, and a quantity in weight of taurine from 0.05% p/p to 90% p/p, preferably from 0.5% p/p to 5% p/p. | 10-14-2010 |
| 20100292332 | RAPID-ACTING, BLOOD-ARGININE-LEVEL-INCREASABLE ORAL PREPARATION COMPRISING CITRULLINE AND ARGININE - The present invention provides a rapid-acting, blood arginine level-increasing oral preparation containing citrulline or a salt thereof and arginine or a salt thereof as active ingredients. The rapid-acting, blood arginine level-increasing oral preparation of the present invention can rapidly and effectively increase blood arginine level after ingestion, and can rapidly provide an arginine ingestion effect. | 11-18-2010 |
| 20100298437 | USE OF CITRULLINE FOR TREATING UNDERNUTRITION CONDITIONS - The invention relates to the use of L-citrulline (I) or of one of its pharmaceutically acceptable salts in the preparation of a drug for the treatment of states or undernutrition as linked to a lowering of protein synthesis within the framework of pathologies which do not result from an intestinal insufficiency. | 11-25-2010 |
| 20100317737 | TOPICAL DELIVERY OF L-ARGININE TO CAUSE BENEFICIAL EFFECTS - The application of L-arginine and its derivatives to the skin causes beneficial effects of wound healing, increasing erectile function and increased growth of hair when applied in sufficient quantity to the skin. A hostile biophysical agent may be combined with the L-arginine to increase its absorption into the skin. The desired concentrations of the hostile biophysical agent is increased when concentration of L-arginine is less than 20% of the concentration of the substance applied to maximize its effect. | 12-16-2010 |
| 20110028553 | TREATING CRITICALLY ILL PATIENTS WITH INTRAVENOUS IBUPROFEN - Methods of treating at least one condition chosen from pain, inflammation, and fever in a critically ill patient in need thereof, comprising administering to the critically ill patient an intravenous pharmaceutical composition comprising ibuprofen using a first dosage regimen, wherein the first dosage regimen produces a first pharmacokinetic profile in critically ill patients that is about equivalent to a second pharmacokinetic profile produced by administration of the intravenous pharmaceutical composition using a second dosage regimen of ibuprofen to non-critically ill patients, wherein the at least one condition of the critically ill patient is thereby treated. | 02-03-2011 |
| 20110060046 | AGENT AND FOOD FOR PREVENTING/IMPROVING FUNCTIONAL DIGESTIVE DISORDER - Provided is an agent for the prophylaxis or improvement of functional gastrointestinal disorders, which contains glutamic acid or a salt thereof other than arginine glutamate, and arginine or a salt thereof other than arginine glutamate, as active ingredients. The prophylactic or improvement agent can be produced conveniently and at low cost and is high safe and particularly effective for functional dyspepsia (FD) such as abdominal pain, heavy stomach, heartburn and the like, and upper gastrointestinal dysfunction such as esophageal reflux (GERD) and the like. | 03-10-2011 |
| 20110130460 | INCREASED CREATINE RETENTION WITH SOLUBLE FIBRES - The present invention generally relates to increasing the efficiency of usage of an ingested biologically active substance by a body. In particular, the present invention relates to ways to improve the efficiency of utilization of ingested creatine in a body, in particular to increase the storage of creatine in the body. One embodiment of the present invention is the use of a combination comprising creatine and a viscous soluble fiber for the preparation of a composition to increase the storage of creatine in the body. | 06-02-2011 |
| 20110166232 | ENHANCEMENT OF UROGENITAL FUNCTION - A method of treating nocturia in a human individual includes administering dosages of creatine to the individual; and reducing the dosages of creatine to the individual responsive to an increase in difficulty of the individual to initiate urination. Another example method includes reducing the dosages of creatine to the individual responsive to an increase in nocturnal urination frequency of the individual. A dosing system includes doses of creatine for treating nocturia in a human individual and is configured for reduced doses for administration in response to an increase in one or more nocturia symptoms. Various other methods as well as compositions, systems, etc., are also disclosed. | 07-07-2011 |
| 20110213033 | SKIN CONDITIONER - The present invention relates to a skin conditioner comprising the compound represented with the general formula: | 09-01-2011 |
| 20110245344 | ARGININE DERIVATIVE AND COSMETIC CONTAINING THE SAME - An object of the invention is to provide a novel arginine derivative and a cosmetic satisfactory in compatibility with the skin and hair, excellent in skin softening effect and skin-conditioning effect, and satisfactory in use feeling with little sticky feeling and tense feeling. | 10-06-2011 |
| 20110313042 | Amino Acid Compositions - An amino acid composition is disclosed. The composition includes: at least one constituent selected from the group consisting of a nitrate, a nitrite, and both; and at least one constituent amino acid selected from the group consisting of Arginine, Agmatine, Beta Alanine, Citrulline, Creatine, Glutamine, L-Histidine, Isoleucine, Leucine, Norvaline, Ornithine, Valine, Aspartic Acid, Cysteine, Glycine, Lysine, Methionine, Proline, Tyrosine, and Phenylalanine Also disclosed are a method for increasing the bioabsorption of Amino Acids in a human or animal and a method for increasing vasodilative characteristics of Amino Acids in a human or animal. | 12-22-2011 |
| 20110313043 | Amino Acid Compositions - Methods for increasing athletic performance, distribution of various Amino Acids to muscles, and solubility of various Amino Acids in a human or animal by administering an amino acid composition that includes: at least one constituent selected from the group consisting of a nitrate, a nitrite, and both; and at least one constituent amino acid selected from the group consisting of Arginine, Agmatine, Beta Alanine, Citrulline, Creatine, Glutamine, L-Histidine, Isoleucine, Leucine, Norvaline, Ornithine, Valine, Aspartic Acid, Cysteine, Glycine, Lysine, Methionine, Proline, Tyrosine, and Phenylalanine | 12-22-2011 |
| 20120010291 | CREATINE Beta-ALANINATE: A NOVEL SALT FOR INCREASING ATHLETIC PERFORMANCE - Disclosed are creatine β-alaninate, compositions and formulations containing same, and methods of use therefor. | 01-12-2012 |
| 20120065266 | ORAL COMPOSITION - The present invention provides an oral composition which can more effectively prevent or improve functional gastrointestinal disorders, particularly upper gastrointestinal dysfunction, specifically functional dyspepsia, and is highly safe and suitable for long-term ingestion. | 03-15-2012 |
| 20120108664 | TRANSDERMAL DELIVERY OF BENEFICIAL SUBSTANCES EFFECTED BY A HOSTILE BIOPHYSICAL ENVIRONMENT - The present invention generally relates to the transdermal delivery of substances In one aspect, various methods for the transdermal delivery of beneficial substances are disclosed. By creating a hostile biophysical environment, beneficial substances may be delivered, according to certain embodiments, through the stratum corneum of the skin into the body. Beneficial substances include, but are not limited to, pharmaceutical agents, drugs, vitamins, co-factors, peptides, dietary supplements, and others. The beneficial effects disclosed include, for instance, relief of pain and inflammation, prevention and healing of ulcers of the skin, relief of headache, improved sexual function and enjoyment, growth of hair on the scalp, improving muscle size and/or function, removing body fat and/or cellulite, treating cancer, treating viral infections and others. A hostile biophysical environment may also be used in conjunction with systems and methods for increasing local blood flow, according to one set of embodiments. | 05-03-2012 |
| 20120172450 | USE OF JASMONATE FOR IMPROVING SKELETAL MUSCLE FUNCTION - A formulation comprising jasmonate for improving skeletal muscle function in a mammal, particularly a human is provided. This may be accomplished by reducing muscle fatigue and/or increasing skeletal muscle performance. | 07-05-2012 |
| 20120238629 | ADDITION COMPOUNDS OF GUANIDINOACETIC ACID - The present invention provides new addition compounds of guanidinoacetic acid with malic acid, aspartic acid, ascorbic acid, succinic acid, pyruvic acid, fumaric acid, gluconic acid, alpha-ketoglutaric acid, pyroglutamic acid, 3-nicotinic acid, lactic acid, citric acid, maleic acid, acetic acid, formic acid, 2-hydroxybenzoic acid, L-carnitine, acetyl-L-carnitine, taurine, betaine, choline, methionine and lipoic acid as well as in the form of sodium, potassium or calcium guanidinoacetate. These addition compounds have improved physiological and therapeutic properties and are particularly suitable for use as dietary supplements, as animal feeds and in cosmetic or dermatological preparations in which especially the marked stability and good bioavailability of the addition compounds come to the fore. | 09-20-2012 |
| 20130102676 | CONTROLLED RELEASE FORMULATIONS OF LEVODOPA AND USES THEREOF - The current invention provides a controlled release oral solid formulation of levodopa comprising levodopa, a decarboxylase inhibitor, and a carboxylic acid. Also provided by this invention is multiparticulate, controlled release oral solid formulations of levodopa comprising: i) a controlled release component comprising a mixture of levodopa, a decarboxylase inhibitor and a rate controlling excipient; ii) a carboxylic acid component; and iii) an immediate release component comprising a mixture of levodopa and a decarboxylase inhibitor. | 04-25-2013 |
| 20130109754 | COMBINATION OF AN NSAID AND AN AMINO ACID | 05-02-2013 |
| 20130116325 | COMPOSITIONS AND METHODS FOR TREATING ANHIDROSIS - Provided herein are compositions and methods useful for the treatment of anhidrosis in mammals, for example, horses. | 05-09-2013 |
| 20130131175 | CREATINE ORAL SUPPLEMENTATION USING CREATINE HYDROCHLORIDE SALT - The present invention is directed to a third generation form of creatine, specifically a creatine hydrochloride salt, that drives significant improvements in muscle development and recovery due to its enhanced bio-availability, while causing fewer negative side effects compared to previous forms of creatine. | 05-23-2013 |
| 20130165517 | Composition and Method for Treating Neurological Disease - A method of treating a patient with Parkinson's disease is provided. The method comprises orally administering to the patient a first agent comprising levodopa and once-daily, orally administering to the patient a second agent comprising amantadine, or a pharmaceutically acceptable salt thereof. The amount of levodopa administered is reduced by 20% to 80% of the amount required in the absence of amantadine. | 06-27-2013 |
| 20130217772 | IBUPROFEN INTRAVENOUS INFUSION - The present invention is a novel pharmaceutical formulation that compromises a four mg per ml (4 mg/mL) Ibuprofen in an aqueous solution of Arginine and Ibuprofen, wherein the molar ratio of Arginine to ibuprofen is more than or equal to 1.000625:1, Tris buffered, isotonic, and adjusted to pH between 7.2-8.5 by addition of 1.0 N HCL, none of the excipients used contains material of animal or human origin. There were no novel excipients used. The present invention also provides a method of treating through anti-inflammatory, analgesic, and antipyretic activity: fever, pain, dysmenorrhea and inflammatory diseases such as rheumatoid arthritis and muscles. It is also used for pericarditis and patent ductus arteriosus (Patent ductus arteriosus (PDA)), relieve moderate to severe pain, dental pain and pain after an operation, also relieve mild to moderate pain including migraine headache, as well as for short term treatment of pyrexia in children over one year of age. The formulation is meant to be used as ready to use intravenous infusion. | 08-22-2013 |
| 20130289119 | FORMULATION COMPRISING ARGININE, USE AND PREPARATION THEREOF - The present invention relates to an edible formulation comprising the following ingredients (% on mix) 19 to 30 weight % of a dietary supplement comprising at least 50% of L-arginine, 20 to 35 weight % of cereal flakes, 14 to 25 weight % of puffed brown or white rice, 12 to 24 weight % of nuts, 9 to 18 weight % of orange rind (or dried fruit such as cranberries, blueberries, raspberry, blackberry) and 2 to 10 weight % of water and/or fruit juice, its use and process of preparation. | 10-31-2013 |
| 20130296431 | GUANIDINO ACETIC ACID USED AS AN ANIMAL FOOD ADDITIVE - The present invention relates to the use of guanidinoacetic acid and/or salts thereof as feed additive, in predominantly vegetarian diets, in particular use being made of salts with hydrochloric acid, hydrobromic acid and phosphoric acid. The use proceeds especially in individual doses from 0.01 to 100 g/kg of feed in the form of powders, granules, pastilles or capsules, the feed additive also being able to be used in combination with other physiologically active materials of value. The claimed use which is suitable especially for breeding and growing livestock, has recourse to a compound which is in particular stable in aqueous solution, can be converted to creatine under physiological conditions, and, in contrast to other guanidine derivatives, is completely available to physiological sectors of use. | 11-07-2013 |
| 20130324609 | DEPRESSION DISORDER THERAPEUTICS WITH CREATINE ANALOGS - In one aspect, the invention relates to creatine analogs, compositions comprising same, and methods of using same, alone or in combination with other agents, to treat depression disorders and associated maladies. This abstract is intended as a scanning tool for purposes of searching in the particular art and is not intended to be limiting of the present invention. | 12-05-2013 |
| 20140018425 | CONTROLLED RELEASE FORMULATIONS OF LEVODOPA AND USES THEREOF - The current invention provides a controlled release oral solid formulation of levodopa comprising levodopa, a decarboxylase inhibitor, and a carboxylic acid. Also provided by this invention is multiparticulate, controlled release oral solid formulations of levodopa comprising: i) a controlled release component comprising a mixture of levodopa, a decarboxylase inhibitor and a rate controlling excipient; ii) a carboxylic acid component; and iii) an immediate release component comprising a mixture of levodopa and a decarboxylase inhibitor. | 01-16-2014 |
| 20140024718 | CONTROLLED RELEASE FORMULATIONS OF LEVODOPA AND USES THEREOF - The current invention provides a controlled release oral solid formulation of levodopa comprising levodopa, a decarboxylase inhibitor, and a carboxylic acid. Also provided by this invention is multiparticulate, controlled release oral solid formulations of levodopa comprising: i) a controlled release component comprising a mixture of levodopa, a decarboxylase inhibitor and a rate controlling excipient; ii) a carboxylic acid component; and iii) an immediate release component comprising a mixture of levodopa and a decarboxylase inhibitor. | 01-23-2014 |
| 20140066511 | TOPICAL DELIVERY OF L-ARGININE TO CAUSE BENEFICIAL EFFECTS - A preparation is disclosed for producing enhanced blood flow in tissue thus causing beneficial effects such as promoting hair growth on scalp tissue lacking sufficient hair, restoring normal sexual function in males with erectile dysfunction. Specifically, this is a preparation which provides local delivery of the amino acid L-arginine, an important biological precursor to the main substance which is responsible for relaxation of blood vessels permitting enhancement of blood flow. In the preferred embodiments, the L-arginine is provided so that it can be topically applied to the scalp or penis. The preparation also contains an agent which aids in the transfer of L-arginine into the tissue. In the preferred embodiments this agent overcomes the resistance to transfer caused by the high charge density of L-arginine. In the preferred embodiments this means is high ionic strength created by addition of choline chloride, magnesium chloride and sodium chloride. This preparation when applied nightly to scalp tissue lacking sufficient hair for a period of time causes substantial growth of hair on the scalp. Further, when applied to the penis of a subject with erectile dysfunction causes restoration of normal sexual function. | 03-06-2014 |
| 20140066512 | ORAL COMPOSITIONS COMPRISING CREATINE - The present invention relates to rehydration and nutritional products comprising creatine and/or its salts, or analogues or precursors thereof, in ready to use aqueous oral compositions, such as gels, pastes and the like, and products for reconstitution in water, for use by humans and animals, together with processes for their preparation and uses thereof. | 03-06-2014 |
| 20140100284 | RAPID-ACTING, BLOOD-ARGININE-LEVEL-INCREASABLE ORAL PREPARATION COMPRISING CITRULLINE AND ARGININE - The present invention provides a rapid-acting, blood arginine level-increasing oral preparation containing citrulline or a salt thereof and arginine or a salt thereof as active ingredients. The rapid-acting, blood arginine level-increasing oral preparation of the present invention can rapidly and effectively increase blood arginine level after ingestion, and can rapidly provide an arginine ingestion effect. | 04-10-2014 |
| 20140107207 | Method for Inactivating Viruses With Slightly Acidic Arginine - The present invention provides a method for conveniently producing a protein formulation in which viruses are inactivated, without impairing the quality of the obtained protein formulation, characterized by including the step of exposing the protein formulation contaminated with the viruses to a 0.1-2M aqueous solution of arginine, an arginine derivative, or a mixture thereof, the aqueous solution being adjusted to pH 3.5 to 5. The present invention also provides a virus inactivation method characterized by including the step of contacting a virus-containing object with a 0.1-2M aqueous solution of arginine, an arginine derivative, or a mixture thereof, the aqueous solution being adjusted to pH 3.5 to 5. | 04-17-2014 |
| 20140142181 | TREATING AND INHIBITING RECURRENCE OF MUSCLE CRAMPS - A method of topical application of a creatine composition for treating and/or inhibiting recurrence of muscle cramps/spasms as well as muscle pain and/or stiffness associated therewith. | 05-22-2014 |
| 20140221489 | Infusion and Injection Solution of Levodopa - A method of eliminating or significantly decreasing shifts between dyskinesia and bradykinesia in a patient suffering from an advanced stage of Parkinson's Disease comprises for a predetermined time period intravenously, subcutaneously or intrathekally administering to the patient by continuous infusion a stable and therapeutically acceptable solution comprising at least 5 mg/ml of Levodopa. | 08-07-2014 |
| 20140235720 | TREATING PATIENTS WITH INTRAVENOUS IBUPROFEN - Methods of treating a patient in need thereof, comprising administering to the critically ill patient an intravenous pharmaceutical composition comprising ibuprofen in an amount effective to treat at least one condition in the patient chosen from pain, inflammation, and fever and to provide a clinically relevant effect on mean arterial pressure of the patients during the dosage interval comprising no increase or no statistically significant increase in mean arterial pressure. | 08-21-2014 |
| 20140249228 | CONTINUOUS ADMINISTRATION OF L-DOPA, DOPA DECARBOXYLASE INHIBITORS, CATECHOL-O-METHYL TRANSFERASE INHIBITORS AND COMPOSITIONS FOR SAME - Provided herein, in part, is a method of treating a neurological or movement disorder in a patient in need thereof, comprising subcutaneously administering to said patient a pharmaceutically acceptable composition comprising levodopa and optionally carbidopa and optionally entacapone or tolcapone, or pharmaceutically acceptable salts thereof, wherein said composition is administered substantially continuously, and compositions that can be used in the disclosed methods. | 09-04-2014 |
| 20140249229 | CONTINUOUS ADMINISTRATION OF L-DOPA, DOPA DECARBOXYLASE INHIBITORS, CATECHOL-O-METHYL TRANSFERASE INHIBITORS AND COMPOSITIONS FOR SAME - Provided herein, in part, is a method of treating a neurological or movement disorder in a patient in need thereof, comprising subcutaneously administering to said patient a pharmaceutically acceptable composition comprising levodopa and optionally carbidopa and optionally entacapone or tolcapone, or pharmaceutically acceptable salts thereof, wherein said composition is administered substantially continuously, and compositions that can be used in the disclosed methods. | 09-04-2014 |
| 20140249230 | Continuous Administration of Dopa Decarboxylase Inhibitors and Compositions for Same - Disclosed herein are compositions that include for example the arginine salt of carbidopa, and methods for treating neurological or movement diseases or disorders such as restless leg syndrome, Parkinson's disease, secondary parkinsonism, Huntington's disease, Parkinson's like syndrome, PSP, MSA, ALS, Shy-Drager syndrome and conditions resulting from brain injury including carbon monoxide or manganese intoxication, using substantially continuous administration of carbidopa or salt thereof together with administration of levodopa. | 09-04-2014 |
| 20140249231 | Continuous Administration of Dopa Decarboxylase Inhibitors and Compositions for Same - Disclosed herein are compositions that include for example the arginine salt of carbidopa, and methods for treating neurological or movement diseases or disorders such as restless leg syndrome, Parkinson's disease, secondary parkinsonism, Huntington's disease, Parkinson's like syndrome, PSP, MSA, ALS, Shy-Drager syndrome and conditions resulting from brain injury including carbon monoxide or manganese intoxication, using substantially continuous administration of carbidopa or salt thereof together with administration of levodopa. | 09-04-2014 |
| 20140309308 | DEPILATORY COMPOSITIONS - The present invention is directed to a depilatory composition which comprisesa depilatory compound having a thiol group; and at least 0.1 wt % of arginine based on the total weight of the composition. | 10-16-2014 |
| 20140343152 | COMPOSITION AND METHOD FOR TREATING NEUROLOGICAL DISEASE - Disclosed are compositions comprising amantadine, or a pharmaceutically acceptable salt thereof, and one or more excipients, wherein at least one of the excipients modifies release of amantadine. Methods of administering the same are also provided. | 11-20-2014 |
| 20140343153 | COMPOSITION AND METHOD FOR TREATING NEUROLOGICAL DISEASE - Disclosed are compositions comprising amantadine, or a pharmaceutically acceptable salt thereof, and one or more excipients, wherein at least one of the excipients modifies release of amantadine. Methods of administering the same are also provided. | 11-20-2014 |
| 20140343154 | COMPOSITION AND METHOD FOR TREATING NEUROLOGICAL DISEASE - Disclosed are compositions comprising amantadine, or a pharmaceutically acceptable salt thereof, and one or more excipients, wherein at least one of the excipients modifies release of amantadine. Methods of administering the same are also provided. | 11-20-2014 |
| 20150119465 | COMPOSITION AND METHOD FOR TREATING NEUROLOGICAL DISEASE - Disclosed are compositions comprising amantadine, or a pharmaceutically acceptable salt thereof, and one or more excipients, wherein at least one of the excipients modifies release of amantadine. Methods of administering the same are also provided. | 04-30-2015 |
| 20150126604 | BRANCHED CHAIN AMINO ACIDS: FORMULATIONS AND METHODS OF TREATMENT - The present disclosure includes a formulation of branched chain amino acids and arginine for treatment of diseases for which the pathological mechanism includes autophagy. The formulation includes defined ratios of the branched chain amino acids Isoleucine, Leucine, and Valine along with Arginine. These disease indications include congestive heart failure, myocardial infarction, and ischemia reperfusion injury. Diseases of other organs that involve autophagy are also disclosed. Additionally, methods of using the disclosed formulation to treat these disease indications are provided. The disclosure also describes a kit that includes a lyophilized form of the formulation, a solvent for reconstitution, and instructions directing reconstitution. | 05-07-2015 |
| 20150126605 | COMPOSITION AND METHOD FOR TREATING NEUROLOGICAL DISEASE - Disclosed are compositions comprising amantadine, or a pharmaceutically acceptable salt thereof, and one or more excipients, wherein at least one of the excipients modifies release of amantadine. Methods of administering the same are also provided. | 05-07-2015 |
| 20150320713 | RAPID-ACTING, BLOOD-ARGININE-LEVEL-INCREASABLE ORAL PREPARATION COMPRISING CITRULLINE AND ARGININE - The invention provides a rapid-acting, blood NO | 11-12-2015 |
| 20150328175 | METHODS FOR PROVIDING RAPID RELIEF OF MOTOR FLUCTUATIONS IN A PARKINSON'S DISEASE PATIENT - The present invention provides methods of providing rapid relief of motor fluctuations in a Parkinson's disease patient. The methods of the invention comprise pulmonary administration of levodopa by inhalation at therapeutically effective concentrations such that the patient's plasma levodopa concentration increases by at least about 200 ng/ml within 10 minutes or less post inhalation as compared to the concentration of levodopa in the patient's plasma prior to inhalation of the levodopa and wherein the patient's plasma concentration remains increased by at least about 200 ng/ml for a time period of at least 15 minutes after inhalation. The methods of the invention are particularly useful for treatment of motor fluctuations which arise as a result of poorly controlled levodopa plasma levels in a patient. | 11-19-2015 |
| 20150352212 | DOPA DECARBOXYLASE INHIBITOR COMPOSITIONS - Disclosed herein are formulations containing carbidopa and optionally levodopa, arginine, and other components that have reduced levels of impurities and toxins, particularly degradation productions. Also disclosed herein are methods of treatment diseases or conditions relating to a loss of dopamine or dopaminergic neurons using such formulations, methods of making such formulations, and kits that include such formulations. | 12-10-2015 |
| 20150362475 | PREDICTION OF KIDNEY DISEASE PROGRESSION USING HOMOARGININE AS A BIOMARKER - The present invention relates to the field of laboratory diagnostics. Specifically, means and methods for determining the progression of chronic kidney disease (CKD) and/or kidney transplant failure including determining the risk of progression of chronic kidney disease (CKD) and/or the risk of kidney transplant failure based on the analysis of homoarginine levels are disclosed. Moreover, the present invention relates to homoarginine for use in a method of treatment and/or prophylaxis of chronic kidney diseases (CKD) as well as for use in a method of treatment and/or prophylaxis of kidney transplant failure in a patient. | 12-17-2015 |
| 20160051502 | METHODS AND COMPOSITIONS FOR INCREASING THE ANAEROBIC WORKING CAPACITY IN TISSUES - Provided are compositions comprising beta-alanylhistidine peptides and/or beta-alanines, and methods for administering these peptides and amino acids. In one aspect, the compositions and methods cause an increase in the blood plasma concentrations of beta-alanine and/or creatine. | 02-25-2016 |
| 20160120829 | HEMODIALYSIS AND PERITONEAL DIALYSIS SOLUTIONS COMPRISING ONE OR MORE CREATINE COMPOUNDS - The present invention provides a hemodialysis solution or concentrate thereof including creatine compound(s), the use of creatine compound(s) for preparing a dialysis solution or concentrate thereof, a method for preparing creatine-containing dialysis solutions and concentrates, and a method for treating patients with dialysis dependent renal failure with creatine compounds to provide a variety of significant health benefits and improvement of life quality parameters for dialysis patients. This is achieve by supporting and improving the physiological functions of organs and cells via creatine compounds delivery to the patients, and by protecting organs and cells of the patients from deleterious effects of a variety of endogenous or exogenous cellular stressors that are linked to the disease state or to the clinical treatment modalities. Furthermore, in peritoneal dialysis solutions creatine can be used as an osmotic agent preventing side effects caused by high glucose supplementation. | 05-05-2016 |
| 20160175272 | COMPOSITIONS AND METHODS FOR TREATMENT OF INFLAMMATION | 06-23-2016 |
| 20160193163 | THERAPEUTIC APPROACHES FOR TREATING PARKINSON'S DISEASE | 07-07-2016 |
| 20220133656 | METHODS OF TREATING TRIGEMINAL NERVE PAIN - Provided are methods for treating trigeminal nerve pain in a subject in need thereof. The method may include administering to the subject by perineural injection of the trigeminal nerve a therapeutically effective amount of a composition comprising an alpha-2 adrenergic agonist, such as guanfacine. The composition may further comprise lidocaine. | 05-05-2022 |
| 20080234380 | Compositions and method for treatment of chronic inflammatory diseases - This invention defines novel compositions that can be used for clinical treatment of a class of chronic inflammatory diseases. Increased generation of carbonyl substances, namely aldehydes and ketones, occurs at sites of chronic inflammation and is common to the etiologies of all of the clinical disorders addressed herein. Such carbonyl substances are cytotoxic and additionally serve to perpetuate and disseminate the inflammatory process. This invention defines use of compositions, the orally administered required primary agents of which are primary amine derivatives of benzoic acid capable of covalently reacting with the carbonyl substances. p-Aminobenzoic acid (or PABA) is an example of the required primary agent of the present invention. PABA has a small molecular weight, is water-soluble, has a primary amine group which reacts with carbonyl-containing substances and is tolerated by the body in relatively high dosages for extended periods. The method of the present invention includes administration of a composition comprising: (1) an orally consumed therapeutically effective amount of at least one required primary agent; (2) at least one required previously known medicament co-agent recognized as effective to treat a chronic inflammatory disease addressed herein administered to the mammalian subject via the oral route; and (3) one or more additional orally consumed required co-agent selected from the group consisting of antioxidants, vitamins, metabolites at risk of depletion, sulfhydryl co-agents, co-agents which may facilitate glutathione activity and nonabsorbable primary amine polymeric co-agents; so as to-produce an additive or synergistic physiological effect of an anti-inflammatory nature. | 09-25-2008 |
| 20080300309 | Creatine Hydroxycitric Acids Salts and Methods for their Production and use in Individuals - Methods of production for Tricreatine Hydroxycitrate are disclosed. Tricreatine hydroxycitrate can be used as supplemental dietary ingredient for the purposes of reducing adiposity, suppression of appetite, improvement of muscle and exercise performance and recovery. The salts are useful in the dietetic, food supplement and food industries. | 12-04-2008 |
| 20080306159 | ENTERIC COATED, SOLUBLE CREATINE AND POLYETHYLENE GLYCOL COMPOSITION FOR ENHANCED SKELETAL UPTAKE OF ORAL CREATINE - An oral creatine formulation includes soluble creatine and polyethylene glycol, coated with an enteric coating. The most preferred soluble creatine is creatine HCl. The most preferred polyethylene glycols have an average molecular weight of from 3150 to 3685, although for particular formulation formulations and particular uses, the average molecular weight polyethylene glycols may range from 190 to 9000. | 12-11-2008 |
| 20090005450 | Use of creatine compounds for the treatment of eye disorders - The present invention provides methods of treating an eye disorder (i.e., glaucoma, macular degeneration, diabetic retinopathy, macular edema, ocular rosacea, amblyopia, cataracts, dry eye, iritis, retinitis pigmentosa, uveitis etc.) by administering a creatine compound to a subject. | 01-01-2009 |
| 20090143470 | Invisible Antimicrobial Glove and Hand Antiseptic - An alcohol based hand surgical scrub, which includes cationic anti-microbial agent preservatives, cationic polymer film-forming agents and a skin emollient, and provides a long term residual, anti-microbial “invisible glove” on the skin. The composition provides an immediate reduction in bacterial microbes. The polymer system creates an invisible film on the skin following solvent evaporation. This invisible film provides a lasting anti-microbial barrier on the skin which acts to prevent microbial growth. | 06-04-2009 |
| 20090163592 | Chiral diacylhydrazine ligands for modulating the expression of exogenous genes via an ecdysone receptor complex - The present invention provides diacylhydrazine ligands and chiral diacylhydrazine ligands for use with ecdysone receptor-based inducible gene expression systems. Thus, the present invention is useful for applications such as gene therapy, large scale production of proteins and antibodies, cell-based screening assays, functional genomics, proteomics, metabolomics, and regulation of traits in transgenic organisms, where control of gene expression levels is desirable. An advantage of the present invention is that it provides a means to regulate gene expression and to tailor expression levels to suit the user's requirements. | 06-25-2009 |
| 20090221706 | Methods of treating cognitive dysfunction by modulating brain energy metabolism - Methods for treating cognitive dysfunction by modulating brain energy metabolism are discussed. | 09-03-2009 |
| 20090253797 | CREATINE ORAL SUPPLEMENTATION USING CREATINE HYDROCHLORIDE SALT - Creatine oral supplementation using creatine hydrochloride salt, that may be added to a liquid or other beverage, or may be also used as an additive to solid oral dosages, or as a supplement, and which may be consumed by the athlete, or other party looking for immediate supplementation of strength, and may be added as a supplement within feed to livestock, in the veterinary area. | 10-08-2009 |
| 20090298943 | Use of creatine analogues and creatine kinase modulators for the prevention and treatment of obesity and its related disorders - The present invention relates to the use of creatine compounds for treating or preventing a metabolic disorder related to body weight control such as obesity, and it's associated diseases in a patient experiencing said disorder. The creatine compounds which can be used in the present method include (1) analogues of creatine which can act as substrates or substrate analogues for the enzyme creatine kinase; (2) compounds which can act as inhibitors of creatine kinase; (3) compounds which can modulate the creatine transporter (4) N-phosphocreatine analogues bearing transferable or non-transferable moieties which mimic the N-phosphoryl group. (5) compounds which modify the association of creatine kinase with other cellular components. | 12-03-2009 |
| 20090312423 | THERAPEUTIC TREATMENT FOR LUNG CONDITIONS - Methods and compositions for treating lung conditions such as bronchopulmonary dysplasia or hypoxia-induced pulmonary hypertension in a subject, including administering to the subject an effective amount of a nitric oxide precursor such as citrulline. | 12-17-2009 |
| 20090318557 | Dermatological compositions - A dermatological composition comprising a salt of a cation and an anion. The cation is derived from a monomeric or polymeric molecule that will generate an amidine moieity, a guanidine moieity or a biguanide moieity. The anion is derived from a monomeric or polymeric molecule that will generate a carboxylic acid moieity. The composition may be prepared by a metathesis or acid-base reaction. | 12-24-2009 |
| 20100022651 | Method For Increasing Hair Growth - The present invention provides a method for stimulating hair growth, which comprises applying a composition containing a combination of a creatine compound and carnitine. The composition may further comprise 5′-AMP and NADH. Such a composition is effective in stimulating cell proliferation in the hair bulb of hair plugs. | 01-28-2010 |
| 20100029768 | Compositions and Methods For Promoting Fat Loss - This invention provides diets useful for promoting fat loss in animals having a total lysine to metabolizable energy ratio of from about 6 to about 10 g/Mcal. This invention also provides compositions for promoting fat loss in animals, methods for preparing the compositions, methods for using the diets and compositions, articles of manufacture comprising the diets and compositions, and means for communicating information or instructions about such diets, compositions, methods, and articles of manufacture. | 02-04-2010 |
| 20100048709 | Treatment of Prostate Cancer with DDC Inhibitor - Prostate cancer comes in various forms and has proven difficult to treat. Provided herein are various methods and compositions for treating all forms of prostate cancers with dopa decarboxylase (DDC) inhibitors. These dopa decarboxylase inhibitors include carbidopa (α-Methyl-dopahydrazine), MFMD (α-monofluoromethyldopa), NSD-1015 (3-hydroxybenzylhydrazine), Methyldopa (L-α-Methyl-3,4-dihydroxyphenylalanine) or benserazide, and the inhibitors may be used in combination. DDC inhibitors may also be used to inhibit the progression of prostate cancer to androgen-independence and neuroendocrine prostate cancer. | 02-25-2010 |
| 20100056633 | SOLID OR AQUEOUS ALKALINE PREPARATION COMPRISING A CREATINE COMPONENT, PROCESS FOR THE PRODUCTION THEREOF AND THE USE THEREOF - A solid or aqueous alkaline preparation comprising a creatine component which comprises a buffer system which adjusts a pH of from 8.0 to 12.0 is described. The creatine is better protected with the aid of the buffer system from conversion into creatinine in the stomach. It has additionally emerged, surprisingly, that the novel formulations display a distinctly higher bioavailability and are thus taken up better by cells. Finally, the preparation of the invention has very good organoleptic properties, which in fact likewise could not be predicted. Owing to these particular advantages, the preparation of the invention is outstandingly suitable as dietary supplements, restoratives, medicinal products and feedstuffs. | 03-04-2010 |
| 20100210728 | COMPOSITION FOR TREATING A DERMAL ANOMALY - An improved composition for treatment of ulcer-type skin conditions. The composition is primarily characterized by a combination of nitroglycerin and arginine. Other embodiments comprise emollient cream, mineral oil, tumeric powder, folic acid, vitamin B12, and zinc citrate. The composition is particularly effective in improving blood flow in the underlying capillary bed about the wound, improving nerve growth about the wound, increasing circulation, and having a standardized and more predictable therapeutic characteristic. | 08-19-2010 |
| 20100227926 | Disinfectant Delivery System, and Method of Providing Alcohol-Free Disinfection - A disinfectant delivery system and method of providing alcohol-free disinfection to a body to be disinfected, as well as a method of infection reduction by preparation of a patient before an invasive procedure. A blended cloth comprising first fibers and second fibers is provided with the first fibers generally being greater in quantity by weight than the second fibers. A disinfectant solution impregnates the blended cloth, with the disinfectant solution having chlorhexidine gluconate as an active ingredient and having no alcohol. In the method according to the invention, at least one impregnated blended cloth is used to disinfect at least a portion of a body. A plurality of blended cloths can be provided for disinfecting discrete portions of the body. When an invasive procedure is to be performed on a patient, a further method according to the invention of infection reduction comprises using a CHG-impregnated cloth to disinfect at least a portion of the patient at least one day prior to the invasive procedure proximate the location of the invasive procedure. | 09-09-2010 |
| 20100261794 | COMPOSITION FOR TOPICAL USE TO ACHIEVE A RAPID AND INTENSE LIFTING EFFECT - This invention concerns a cosmetic composition for topical use containing as an active principle a blend of arginine and taurine designed to carry out an immediate “lifting” effect and able to improve in a short time the aesthetic characteristics of the cutis. The composition contains a quantity in weight of arginine of 0.05% p/p at 90% p/p, preferably from 0.5% p/p to 5% p/p, and a quantity in weight of taurine from 0.05% p/p to 90% p/p, preferably from 0.5% p/p to 5% p/p. | 10-14-2010 |
| 20100292332 | RAPID-ACTING, BLOOD-ARGININE-LEVEL-INCREASABLE ORAL PREPARATION COMPRISING CITRULLINE AND ARGININE - The present invention provides a rapid-acting, blood arginine level-increasing oral preparation containing citrulline or a salt thereof and arginine or a salt thereof as active ingredients. The rapid-acting, blood arginine level-increasing oral preparation of the present invention can rapidly and effectively increase blood arginine level after ingestion, and can rapidly provide an arginine ingestion effect. | 11-18-2010 |
| 20100298437 | USE OF CITRULLINE FOR TREATING UNDERNUTRITION CONDITIONS - The invention relates to the use of L-citrulline (I) or of one of its pharmaceutically acceptable salts in the preparation of a drug for the treatment of states or undernutrition as linked to a lowering of protein synthesis within the framework of pathologies which do not result from an intestinal insufficiency. | 11-25-2010 |
| 20100317737 | TOPICAL DELIVERY OF L-ARGININE TO CAUSE BENEFICIAL EFFECTS - The application of L-arginine and its derivatives to the skin causes beneficial effects of wound healing, increasing erectile function and increased growth of hair when applied in sufficient quantity to the skin. A hostile biophysical agent may be combined with the L-arginine to increase its absorption into the skin. The desired concentrations of the hostile biophysical agent is increased when concentration of L-arginine is less than 20% of the concentration of the substance applied to maximize its effect. | 12-16-2010 |
| 20110028553 | TREATING CRITICALLY ILL PATIENTS WITH INTRAVENOUS IBUPROFEN - Methods of treating at least one condition chosen from pain, inflammation, and fever in a critically ill patient in need thereof, comprising administering to the critically ill patient an intravenous pharmaceutical composition comprising ibuprofen using a first dosage regimen, wherein the first dosage regimen produces a first pharmacokinetic profile in critically ill patients that is about equivalent to a second pharmacokinetic profile produced by administration of the intravenous pharmaceutical composition using a second dosage regimen of ibuprofen to non-critically ill patients, wherein the at least one condition of the critically ill patient is thereby treated. | 02-03-2011 |
| 20110060046 | AGENT AND FOOD FOR PREVENTING/IMPROVING FUNCTIONAL DIGESTIVE DISORDER - Provided is an agent for the prophylaxis or improvement of functional gastrointestinal disorders, which contains glutamic acid or a salt thereof other than arginine glutamate, and arginine or a salt thereof other than arginine glutamate, as active ingredients. The prophylactic or improvement agent can be produced conveniently and at low cost and is high safe and particularly effective for functional dyspepsia (FD) such as abdominal pain, heavy stomach, heartburn and the like, and upper gastrointestinal dysfunction such as esophageal reflux (GERD) and the like. | 03-10-2011 |
| 20110130460 | INCREASED CREATINE RETENTION WITH SOLUBLE FIBRES - The present invention generally relates to increasing the efficiency of usage of an ingested biologically active substance by a body. In particular, the present invention relates to ways to improve the efficiency of utilization of ingested creatine in a body, in particular to increase the storage of creatine in the body. One embodiment of the present invention is the use of a combination comprising creatine and a viscous soluble fiber for the preparation of a composition to increase the storage of creatine in the body. | 06-02-2011 |
| 20110166232 | ENHANCEMENT OF UROGENITAL FUNCTION - A method of treating nocturia in a human individual includes administering dosages of creatine to the individual; and reducing the dosages of creatine to the individual responsive to an increase in difficulty of the individual to initiate urination. Another example method includes reducing the dosages of creatine to the individual responsive to an increase in nocturnal urination frequency of the individual. A dosing system includes doses of creatine for treating nocturia in a human individual and is configured for reduced doses for administration in response to an increase in one or more nocturia symptoms. Various other methods as well as compositions, systems, etc., are also disclosed. | 07-07-2011 |
| 20110213033 | SKIN CONDITIONER - The present invention relates to a skin conditioner comprising the compound represented with the general formula: | 09-01-2011 |
| 20110245344 | ARGININE DERIVATIVE AND COSMETIC CONTAINING THE SAME - An object of the invention is to provide a novel arginine derivative and a cosmetic satisfactory in compatibility with the skin and hair, excellent in skin softening effect and skin-conditioning effect, and satisfactory in use feeling with little sticky feeling and tense feeling. | 10-06-2011 |
| 20110313042 | Amino Acid Compositions - An amino acid composition is disclosed. The composition includes: at least one constituent selected from the group consisting of a nitrate, a nitrite, and both; and at least one constituent amino acid selected from the group consisting of Arginine, Agmatine, Beta Alanine, Citrulline, Creatine, Glutamine, L-Histidine, Isoleucine, Leucine, Norvaline, Ornithine, Valine, Aspartic Acid, Cysteine, Glycine, Lysine, Methionine, Proline, Tyrosine, and Phenylalanine Also disclosed are a method for increasing the bioabsorption of Amino Acids in a human or animal and a method for increasing vasodilative characteristics of Amino Acids in a human or animal. | 12-22-2011 |
| 20110313043 | Amino Acid Compositions - Methods for increasing athletic performance, distribution of various Amino Acids to muscles, and solubility of various Amino Acids in a human or animal by administering an amino acid composition that includes: at least one constituent selected from the group consisting of a nitrate, a nitrite, and both; and at least one constituent amino acid selected from the group consisting of Arginine, Agmatine, Beta Alanine, Citrulline, Creatine, Glutamine, L-Histidine, Isoleucine, Leucine, Norvaline, Ornithine, Valine, Aspartic Acid, Cysteine, Glycine, Lysine, Methionine, Proline, Tyrosine, and Phenylalanine | 12-22-2011 |
| 20120010291 | CREATINE Beta-ALANINATE: A NOVEL SALT FOR INCREASING ATHLETIC PERFORMANCE - Disclosed are creatine β-alaninate, compositions and formulations containing same, and methods of use therefor. | 01-12-2012 |
| 20120065266 | ORAL COMPOSITION - The present invention provides an oral composition which can more effectively prevent or improve functional gastrointestinal disorders, particularly upper gastrointestinal dysfunction, specifically functional dyspepsia, and is highly safe and suitable for long-term ingestion. | 03-15-2012 |
| 20120108664 | TRANSDERMAL DELIVERY OF BENEFICIAL SUBSTANCES EFFECTED BY A HOSTILE BIOPHYSICAL ENVIRONMENT - The present invention generally relates to the transdermal delivery of substances In one aspect, various methods for the transdermal delivery of beneficial substances are disclosed. By creating a hostile biophysical environment, beneficial substances may be delivered, according to certain embodiments, through the stratum corneum of the skin into the body. Beneficial substances include, but are not limited to, pharmaceutical agents, drugs, vitamins, co-factors, peptides, dietary supplements, and others. The beneficial effects disclosed include, for instance, relief of pain and inflammation, prevention and healing of ulcers of the skin, relief of headache, improved sexual function and enjoyment, growth of hair on the scalp, improving muscle size and/or function, removing body fat and/or cellulite, treating cancer, treating viral infections and others. A hostile biophysical environment may also be used in conjunction with systems and methods for increasing local blood flow, according to one set of embodiments. | 05-03-2012 |
| 20120172450 | USE OF JASMONATE FOR IMPROVING SKELETAL MUSCLE FUNCTION - A formulation comprising jasmonate for improving skeletal muscle function in a mammal, particularly a human is provided. This may be accomplished by reducing muscle fatigue and/or increasing skeletal muscle performance. | 07-05-2012 |
| 20120238629 | ADDITION COMPOUNDS OF GUANIDINOACETIC ACID - The present invention provides new addition compounds of guanidinoacetic acid with malic acid, aspartic acid, ascorbic acid, succinic acid, pyruvic acid, fumaric acid, gluconic acid, alpha-ketoglutaric acid, pyroglutamic acid, 3-nicotinic acid, lactic acid, citric acid, maleic acid, acetic acid, formic acid, 2-hydroxybenzoic acid, L-carnitine, acetyl-L-carnitine, taurine, betaine, choline, methionine and lipoic acid as well as in the form of sodium, potassium or calcium guanidinoacetate. These addition compounds have improved physiological and therapeutic properties and are particularly suitable for use as dietary supplements, as animal feeds and in cosmetic or dermatological preparations in which especially the marked stability and good bioavailability of the addition compounds come to the fore. | 09-20-2012 |
| 20130102676 | CONTROLLED RELEASE FORMULATIONS OF LEVODOPA AND USES THEREOF - The current invention provides a controlled release oral solid formulation of levodopa comprising levodopa, a decarboxylase inhibitor, and a carboxylic acid. Also provided by this invention is multiparticulate, controlled release oral solid formulations of levodopa comprising: i) a controlled release component comprising a mixture of levodopa, a decarboxylase inhibitor and a rate controlling excipient; ii) a carboxylic acid component; and iii) an immediate release component comprising a mixture of levodopa and a decarboxylase inhibitor. | 04-25-2013 |
| 20130109754 | COMBINATION OF AN NSAID AND AN AMINO ACID | 05-02-2013 |
| 20130116325 | COMPOSITIONS AND METHODS FOR TREATING ANHIDROSIS - Provided herein are compositions and methods useful for the treatment of anhidrosis in mammals, for example, horses. | 05-09-2013 |
| 20130131175 | CREATINE ORAL SUPPLEMENTATION USING CREATINE HYDROCHLORIDE SALT - The present invention is directed to a third generation form of creatine, specifically a creatine hydrochloride salt, that drives significant improvements in muscle development and recovery due to its enhanced bio-availability, while causing fewer negative side effects compared to previous forms of creatine. | 05-23-2013 |
| 20130165517 | Composition and Method for Treating Neurological Disease - A method of treating a patient with Parkinson's disease is provided. The method comprises orally administering to the patient a first agent comprising levodopa and once-daily, orally administering to the patient a second agent comprising amantadine, or a pharmaceutically acceptable salt thereof. The amount of levodopa administered is reduced by 20% to 80% of the amount required in the absence of amantadine. | 06-27-2013 |
| 20130217772 | IBUPROFEN INTRAVENOUS INFUSION - The present invention is a novel pharmaceutical formulation that compromises a four mg per ml (4 mg/mL) Ibuprofen in an aqueous solution of Arginine and Ibuprofen, wherein the molar ratio of Arginine to ibuprofen is more than or equal to 1.000625:1, Tris buffered, isotonic, and adjusted to pH between 7.2-8.5 by addition of 1.0 N HCL, none of the excipients used contains material of animal or human origin. There were no novel excipients used. The present invention also provides a method of treating through anti-inflammatory, analgesic, and antipyretic activity: fever, pain, dysmenorrhea and inflammatory diseases such as rheumatoid arthritis and muscles. It is also used for pericarditis and patent ductus arteriosus (Patent ductus arteriosus (PDA)), relieve moderate to severe pain, dental pain and pain after an operation, also relieve mild to moderate pain including migraine headache, as well as for short term treatment of pyrexia in children over one year of age. The formulation is meant to be used as ready to use intravenous infusion. | 08-22-2013 |
| 20130289119 | FORMULATION COMPRISING ARGININE, USE AND PREPARATION THEREOF - The present invention relates to an edible formulation comprising the following ingredients (% on mix) 19 to 30 weight % of a dietary supplement comprising at least 50% of L-arginine, 20 to 35 weight % of cereal flakes, 14 to 25 weight % of puffed brown or white rice, 12 to 24 weight % of nuts, 9 to 18 weight % of orange rind (or dried fruit such as cranberries, blueberries, raspberry, blackberry) and 2 to 10 weight % of water and/or fruit juice, its use and process of preparation. | 10-31-2013 |
| 20130296431 | GUANIDINO ACETIC ACID USED AS AN ANIMAL FOOD ADDITIVE - The present invention relates to the use of guanidinoacetic acid and/or salts thereof as feed additive, in predominantly vegetarian diets, in particular use being made of salts with hydrochloric acid, hydrobromic acid and phosphoric acid. The use proceeds especially in individual doses from 0.01 to 100 g/kg of feed in the form of powders, granules, pastilles or capsules, the feed additive also being able to be used in combination with other physiologically active materials of value. The claimed use which is suitable especially for breeding and growing livestock, has recourse to a compound which is in particular stable in aqueous solution, can be converted to creatine under physiological conditions, and, in contrast to other guanidine derivatives, is completely available to physiological sectors of use. | 11-07-2013 |
| 20130324609 | DEPRESSION DISORDER THERAPEUTICS WITH CREATINE ANALOGS - In one aspect, the invention relates to creatine analogs, compositions comprising same, and methods of using same, alone or in combination with other agents, to treat depression disorders and associated maladies. This abstract is intended as a scanning tool for purposes of searching in the particular art and is not intended to be limiting of the present invention. | 12-05-2013 |
| 20140018425 | CONTROLLED RELEASE FORMULATIONS OF LEVODOPA AND USES THEREOF - The current invention provides a controlled release oral solid formulation of levodopa comprising levodopa, a decarboxylase inhibitor, and a carboxylic acid. Also provided by this invention is multiparticulate, controlled release oral solid formulations of levodopa comprising: i) a controlled release component comprising a mixture of levodopa, a decarboxylase inhibitor and a rate controlling excipient; ii) a carboxylic acid component; and iii) an immediate release component comprising a mixture of levodopa and a decarboxylase inhibitor. | 01-16-2014 |
| 20140024718 | CONTROLLED RELEASE FORMULATIONS OF LEVODOPA AND USES THEREOF - The current invention provides a controlled release oral solid formulation of levodopa comprising levodopa, a decarboxylase inhibitor, and a carboxylic acid. Also provided by this invention is multiparticulate, controlled release oral solid formulations of levodopa comprising: i) a controlled release component comprising a mixture of levodopa, a decarboxylase inhibitor and a rate controlling excipient; ii) a carboxylic acid component; and iii) an immediate release component comprising a mixture of levodopa and a decarboxylase inhibitor. | 01-23-2014 |
| 20140066511 | TOPICAL DELIVERY OF L-ARGININE TO CAUSE BENEFICIAL EFFECTS - A preparation is disclosed for producing enhanced blood flow in tissue thus causing beneficial effects such as promoting hair growth on scalp tissue lacking sufficient hair, restoring normal sexual function in males with erectile dysfunction. Specifically, this is a preparation which provides local delivery of the amino acid L-arginine, an important biological precursor to the main substance which is responsible for relaxation of blood vessels permitting enhancement of blood flow. In the preferred embodiments, the L-arginine is provided so that it can be topically applied to the scalp or penis. The preparation also contains an agent which aids in the transfer of L-arginine into the tissue. In the preferred embodiments this agent overcomes the resistance to transfer caused by the high charge density of L-arginine. In the preferred embodiments this means is high ionic strength created by addition of choline chloride, magnesium chloride and sodium chloride. This preparation when applied nightly to scalp tissue lacking sufficient hair for a period of time causes substantial growth of hair on the scalp. Further, when applied to the penis of a subject with erectile dysfunction causes restoration of normal sexual function. | 03-06-2014 |
| 20140066512 | ORAL COMPOSITIONS COMPRISING CREATINE - The present invention relates to rehydration and nutritional products comprising creatine and/or its salts, or analogues or precursors thereof, in ready to use aqueous oral compositions, such as gels, pastes and the like, and products for reconstitution in water, for use by humans and animals, together with processes for their preparation and uses thereof. | 03-06-2014 |
| 20140100284 | RAPID-ACTING, BLOOD-ARGININE-LEVEL-INCREASABLE ORAL PREPARATION COMPRISING CITRULLINE AND ARGININE - The present invention provides a rapid-acting, blood arginine level-increasing oral preparation containing citrulline or a salt thereof and arginine or a salt thereof as active ingredients. The rapid-acting, blood arginine level-increasing oral preparation of the present invention can rapidly and effectively increase blood arginine level after ingestion, and can rapidly provide an arginine ingestion effect. | 04-10-2014 |
| 20140107207 | Method for Inactivating Viruses With Slightly Acidic Arginine - The present invention provides a method for conveniently producing a protein formulation in which viruses are inactivated, without impairing the quality of the obtained protein formulation, characterized by including the step of exposing the protein formulation contaminated with the viruses to a 0.1-2M aqueous solution of arginine, an arginine derivative, or a mixture thereof, the aqueous solution being adjusted to pH 3.5 to 5. The present invention also provides a virus inactivation method characterized by including the step of contacting a virus-containing object with a 0.1-2M aqueous solution of arginine, an arginine derivative, or a mixture thereof, the aqueous solution being adjusted to pH 3.5 to 5. | 04-17-2014 |
| 20140142181 | TREATING AND INHIBITING RECURRENCE OF MUSCLE CRAMPS - A method of topical application of a creatine composition for treating and/or inhibiting recurrence of muscle cramps/spasms as well as muscle pain and/or stiffness associated therewith. | 05-22-2014 |
| 20140221489 | Infusion and Injection Solution of Levodopa - A method of eliminating or significantly decreasing shifts between dyskinesia and bradykinesia in a patient suffering from an advanced stage of Parkinson's Disease comprises for a predetermined time period intravenously, subcutaneously or intrathekally administering to the patient by continuous infusion a stable and therapeutically acceptable solution comprising at least 5 mg/ml of Levodopa. | 08-07-2014 |
| 20140235720 | TREATING PATIENTS WITH INTRAVENOUS IBUPROFEN - Methods of treating a patient in need thereof, comprising administering to the critically ill patient an intravenous pharmaceutical composition comprising ibuprofen in an amount effective to treat at least one condition in the patient chosen from pain, inflammation, and fever and to provide a clinically relevant effect on mean arterial pressure of the patients during the dosage interval comprising no increase or no statistically significant increase in mean arterial pressure. | 08-21-2014 |
| 20140249228 | CONTINUOUS ADMINISTRATION OF L-DOPA, DOPA DECARBOXYLASE INHIBITORS, CATECHOL-O-METHYL TRANSFERASE INHIBITORS AND COMPOSITIONS FOR SAME - Provided herein, in part, is a method of treating a neurological or movement disorder in a patient in need thereof, comprising subcutaneously administering to said patient a pharmaceutically acceptable composition comprising levodopa and optionally carbidopa and optionally entacapone or tolcapone, or pharmaceutically acceptable salts thereof, wherein said composition is administered substantially continuously, and compositions that can be used in the disclosed methods. | 09-04-2014 |
| 20140249229 | CONTINUOUS ADMINISTRATION OF L-DOPA, DOPA DECARBOXYLASE INHIBITORS, CATECHOL-O-METHYL TRANSFERASE INHIBITORS AND COMPOSITIONS FOR SAME - Provided herein, in part, is a method of treating a neurological or movement disorder in a patient in need thereof, comprising subcutaneously administering to said patient a pharmaceutically acceptable composition comprising levodopa and optionally carbidopa and optionally entacapone or tolcapone, or pharmaceutically acceptable salts thereof, wherein said composition is administered substantially continuously, and compositions that can be used in the disclosed methods. | 09-04-2014 |
| 20140249230 | Continuous Administration of Dopa Decarboxylase Inhibitors and Compositions for Same - Disclosed herein are compositions that include for example the arginine salt of carbidopa, and methods for treating neurological or movement diseases or disorders such as restless leg syndrome, Parkinson's disease, secondary parkinsonism, Huntington's disease, Parkinson's like syndrome, PSP, MSA, ALS, Shy-Drager syndrome and conditions resulting from brain injury including carbon monoxide or manganese intoxication, using substantially continuous administration of carbidopa or salt thereof together with administration of levodopa. | 09-04-2014 |
| 20140249231 | Continuous Administration of Dopa Decarboxylase Inhibitors and Compositions for Same - Disclosed herein are compositions that include for example the arginine salt of carbidopa, and methods for treating neurological or movement diseases or disorders such as restless leg syndrome, Parkinson's disease, secondary parkinsonism, Huntington's disease, Parkinson's like syndrome, PSP, MSA, ALS, Shy-Drager syndrome and conditions resulting from brain injury including carbon monoxide or manganese intoxication, using substantially continuous administration of carbidopa or salt thereof together with administration of levodopa. | 09-04-2014 |
| 20140309308 | DEPILATORY COMPOSITIONS - The present invention is directed to a depilatory composition which comprisesa depilatory compound having a thiol group; and at least 0.1 wt % of arginine based on the total weight of the composition. | 10-16-2014 |
| 20140343152 | COMPOSITION AND METHOD FOR TREATING NEUROLOGICAL DISEASE - Disclosed are compositions comprising amantadine, or a pharmaceutically acceptable salt thereof, and one or more excipients, wherein at least one of the excipients modifies release of amantadine. Methods of administering the same are also provided. | 11-20-2014 |
| 20140343153 | COMPOSITION AND METHOD FOR TREATING NEUROLOGICAL DISEASE - Disclosed are compositions comprising amantadine, or a pharmaceutically acceptable salt thereof, and one or more excipients, wherein at least one of the excipients modifies release of amantadine. Methods of administering the same are also provided. | 11-20-2014 |
| 20140343154 | COMPOSITION AND METHOD FOR TREATING NEUROLOGICAL DISEASE - Disclosed are compositions comprising amantadine, or a pharmaceutically acceptable salt thereof, and one or more excipients, wherein at least one of the excipients modifies release of amantadine. Methods of administering the same are also provided. | 11-20-2014 |
| 20150119465 | COMPOSITION AND METHOD FOR TREATING NEUROLOGICAL DISEASE - Disclosed are compositions comprising amantadine, or a pharmaceutically acceptable salt thereof, and one or more excipients, wherein at least one of the excipients modifies release of amantadine. Methods of administering the same are also provided. | 04-30-2015 |
| 20150126604 | BRANCHED CHAIN AMINO ACIDS: FORMULATIONS AND METHODS OF TREATMENT - The present disclosure includes a formulation of branched chain amino acids and arginine for treatment of diseases for which the pathological mechanism includes autophagy. The formulation includes defined ratios of the branched chain amino acids Isoleucine, Leucine, and Valine along with Arginine. These disease indications include congestive heart failure, myocardial infarction, and ischemia reperfusion injury. Diseases of other organs that involve autophagy are also disclosed. Additionally, methods of using the disclosed formulation to treat these disease indications are provided. The disclosure also describes a kit that includes a lyophilized form of the formulation, a solvent for reconstitution, and instructions directing reconstitution. | 05-07-2015 |
| 20150126605 | COMPOSITION AND METHOD FOR TREATING NEUROLOGICAL DISEASE - Disclosed are compositions comprising amantadine, or a pharmaceutically acceptable salt thereof, and one or more excipients, wherein at least one of the excipients modifies release of amantadine. Methods of administering the same are also provided. | 05-07-2015 |
| 20150320713 | RAPID-ACTING, BLOOD-ARGININE-LEVEL-INCREASABLE ORAL PREPARATION COMPRISING CITRULLINE AND ARGININE - The invention provides a rapid-acting, blood NO | 11-12-2015 |
| 20150328175 | METHODS FOR PROVIDING RAPID RELIEF OF MOTOR FLUCTUATIONS IN A PARKINSON'S DISEASE PATIENT - The present invention provides methods of providing rapid relief of motor fluctuations in a Parkinson's disease patient. The methods of the invention comprise pulmonary administration of levodopa by inhalation at therapeutically effective concentrations such that the patient's plasma levodopa concentration increases by at least about 200 ng/ml within 10 minutes or less post inhalation as compared to the concentration of levodopa in the patient's plasma prior to inhalation of the levodopa and wherein the patient's plasma concentration remains increased by at least about 200 ng/ml for a time period of at least 15 minutes after inhalation. The methods of the invention are particularly useful for treatment of motor fluctuations which arise as a result of poorly controlled levodopa plasma levels in a patient. | 11-19-2015 |
| 20150352212 | DOPA DECARBOXYLASE INHIBITOR COMPOSITIONS - Disclosed herein are formulations containing carbidopa and optionally levodopa, arginine, and other components that have reduced levels of impurities and toxins, particularly degradation productions. Also disclosed herein are methods of treatment diseases or conditions relating to a loss of dopamine or dopaminergic neurons using such formulations, methods of making such formulations, and kits that include such formulations. | 12-10-2015 |
| 20150362475 | PREDICTION OF KIDNEY DISEASE PROGRESSION USING HOMOARGININE AS A BIOMARKER - The present invention relates to the field of laboratory diagnostics. Specifically, means and methods for determining the progression of chronic kidney disease (CKD) and/or kidney transplant failure including determining the risk of progression of chronic kidney disease (CKD) and/or the risk of kidney transplant failure based on the analysis of homoarginine levels are disclosed. Moreover, the present invention relates to homoarginine for use in a method of treatment and/or prophylaxis of chronic kidney diseases (CKD) as well as for use in a method of treatment and/or prophylaxis of kidney transplant failure in a patient. | 12-17-2015 |
| 20160051502 | METHODS AND COMPOSITIONS FOR INCREASING THE ANAEROBIC WORKING CAPACITY IN TISSUES - Provided are compositions comprising beta-alanylhistidine peptides and/or beta-alanines, and methods for administering these peptides and amino acids. In one aspect, the compositions and methods cause an increase in the blood plasma concentrations of beta-alanine and/or creatine. | 02-25-2016 |
| 20160120829 | HEMODIALYSIS AND PERITONEAL DIALYSIS SOLUTIONS COMPRISING ONE OR MORE CREATINE COMPOUNDS - The present invention provides a hemodialysis solution or concentrate thereof including creatine compound(s), the use of creatine compound(s) for preparing a dialysis solution or concentrate thereof, a method for preparing creatine-containing dialysis solutions and concentrates, and a method for treating patients with dialysis dependent renal failure with creatine compounds to provide a variety of significant health benefits and improvement of life quality parameters for dialysis patients. This is achieve by supporting and improving the physiological functions of organs and cells via creatine compounds delivery to the patients, and by protecting organs and cells of the patients from deleterious effects of a variety of endogenous or exogenous cellular stressors that are linked to the disease state or to the clinical treatment modalities. Furthermore, in peritoneal dialysis solutions creatine can be used as an osmotic agent preventing side effects caused by high glucose supplementation. | 05-05-2016 |
| 20160175272 | COMPOSITIONS AND METHODS FOR TREATMENT OF INFLAMMATION | 06-23-2016 |
| 20160193163 | THERAPEUTIC APPROACHES FOR TREATING PARKINSON'S DISEASE | 07-07-2016 |
| 20220133656 | METHODS OF TREATING TRIGEMINAL NERVE PAIN - Provided are methods for treating trigeminal nerve pain in a subject in need thereof. The method may include administering to the subject by perineural injection of the trigeminal nerve a therapeutically effective amount of a composition comprising an alpha-2 adrenergic agonist, such as guanfacine. The composition may further comprise lidocaine. | 05-05-2022 |
